Immunocore Holdings plc

Immunocore Holdings plc reported its third-quarter financial results, showing a net loss of $14.22 million, or $0.28 per share, compared to a net loss of $0.18 million in the same period last year. Revenue from the sale of therapies was $102.22 million, a slight decrease from $103.69 million in the prior year's quarter. The company's balance sheet shows an increase in total assets to $1.13 billion and a healthy cash position of $512.25 million. The filing also details ongoing clinical programs and forward-looking statements regarding therapeutic potential and market expansion.

Immunocore Holdings plc reported its third quarter financial results for the period ended September 30, 2026. KIMMTRAK net revenues for Q3 2026 were $102.2 million, a slight decrease year-over-year, but year-to-date net revenues reached $324.8 million, marking a 10% increase. The company also provided a business update, highlighting the completion of enrollment for the Phase 3 TEBE-AM trial and the dosing of the first patient in the IMC-S118AI Phase 1 trial for type 1 diabetes. The company reported a net loss of $14.2 million for the quarter, compared to a net loss of $0.2 million in the prior year period, with R&D expenses increasing to $74.7 million.

Immunocore Holdings plc reported Q3 2026 financial results, with KIMMTRAK net revenues at $102.2 million, contributing to $324.8 million year-to-date. The company announced the completion of enrollment for its Phase 3 TEBE-AM trial for advanced cutaneous melanoma, with data anticipated in Q2 2027. Additionally, the first patient was dosed in the Phase 1 trial for IMC-S118AI, an autoimmune candidate for type 1 diabetes. While net revenues showed a slight decrease year-over-year for the quarter, the year-to-date net loss improved significantly. The company ended the quarter with $901.3 million in cash, cash equivalents, and marketable securities.

Immunocore Holdings plc reported strong financial results for Q2 2026, with revenue from therapy sales increasing to $115.9 million, up from $98.0 million in Q2 2025. For the six months ended June 30, 2026, the company achieved a net income of $12.2 million, a significant improvement from a net loss of $5.3 million in the prior year period. Basic net income per share for the six-month period was $0.24. The company also saw an increase in cash and cash equivalents to $484.9 million, reflecting continued commercial expansion of KIMMTRAK.

Immunocore reported Q2 2026 KIMMTRAK net revenues of $115.9 million, an 18% increase year-over-year, and a net loss of $0.8 million. For the first half of 2026, the company achieved a net income of $12.2 million. The company also announced that enrollment in its Phase 3 TEBE-AM trial is nearing completion, with data expected by the end of 2026, and presented positive five-year overall survival data for KIMMTRAK in metastatic uveal melanoma.

Immunocore presented updated Phase 1/2 data for brenetafusp in heavily pretreated advanced melanoma at the 2026 ASCO Annual Meeting. Brenetafusp monotherapy resulted in an 87% 6-month overall survival rate and a 52% disease control rate in HLA-A*02:01-positive patients. These promising results support the selection of the 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma. The drug was generally well tolerated, with consistent clinical benefit observed even in difficult-to-treat subgroups.

Immunocore Holdings plc reported strong financial results for Q1 2026, with net income surging by 158.2% to $13.0 million and total revenue from therapy sales increasing by 13.6% to $106.7 million. The company highlighted the continued global expansion of its lead product, KIMMTRAK, now approved in 39 countries and commercially launched in over 30. Immunocore is also advancing its clinical pipeline and strategic priorities for 2026.

Immunocore reported strong first-quarter 2026 financial results, with KIMMTRAK net sales reaching $106.7 million, a 14% increase year-over-year. The company achieved a net income of $13.0 million, up from $5.0 million in Q1 2025. A significant highlight was the oral presentation at AACR, showing KIMMTRAK doubled the likelihood of being alive at five years for metastatic uveal melanoma patients. Immunocore also provided updates on its pipeline, including progress in trials for advanced cutaneous melanoma and autoimmune diseases, and maintained a strong cash position of $845 million.